Global COVID-19 Sample Collection Kits Market: By Product Type (Swabs, Viral Transport Media, Blood Collection Kits, Others), Application (Diagnostics, Research), End-User (Hospitals & Clinics, Diagnostic Centers, Others) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2027

Market Forecast

Global COVID-19 Sample Collection Kits Market is expected to hold a value of USD 4168.35 Million by 2027 and is expected to register a growth of 5.20% from 2020 to 2027.

Market Synopsis

The sample collection kit means the vitals and reagents provided for use in collecting samples and shipping them to the laboratory at which the testing services will be performed on such a sample. The high demand for sample collection kits, due to the outbreak of COVID-19 globally, and approval of new & advanced detection tests by authorities are the key factors that are expected to drive the market growth. The Food and Drug Administration (FDA), in May 2020, has issued an emergency use authorization (EUA) to Everlywell, Inc. for the COVID-19 Test Home Collection Kit. The product is a standalone, at home, nasal swab sample collection kit that can be sent to specified labs for subsequent COVID-19 diagnostic testing. Thus, there is an increase in demand for sample collection kits. Moreover, the detection of antibodies, rise in government funding, and large volume of products & usage rate of swabs are also expected to boost the market growth.

Market Influencer

The outbreak of COVID-19, leading to increased demand for the COVID-19 sample collection kit.

Market Drivers

• High demand for sample collection kits, due to the outbreak of COVID-19 globally.

• Approval of detection tests by regulatory authorities. These tests are based on four different techniques such as reverse transcription-polymerase chain reaction (RT-PCR), loop-mediated isothermal amplification (LAMP), Lateral flow, and Enzyme-linked immunosorbent assay (ELISA).

• Large volume and usage rate of swabs. California- based medical device manufacturer, IPB Inc. has been working for the production of new swabs, nearly 2, 00,000 per day.

• Rise in the detection of antibodies

• Increase in government funding.

• Rise in at-home kits for reducing the risk of transmitting the virus.

Market Restraints

• Shortage of test-related supplies such as reverse transcription-polymerase chain reaction instruments, swabs, and virus control samples to control.

• Lack of laboratory-based reagents

Segmentation

By Product Type

• Swabs: Swabs are a small piece of soft material used for cleaning a cut or for taking a small amount of substance from a body, or the substance itself that can be tested. According to the Centers for Disease Control and Prevention (CDC), May 2020 report, sterile swabs for upper respiratory specimen collection can be packaged in two ways i.e., individually wrapped and bulk packaged.
  
  
  
  • Nasopharyngeal (NP) Swabs: A nasopharyngeal swab is a method for collecting a clinical test sample of nasal secretions from the back of the nose and throat. This is the fastest-growing segment.
  
  
  • Oropharyngeal (OP) Swabs: An oropharyngeal swab is a method to identify germs or viruses that may cause infection in the throat.
  
  
  
  

• Viral Transport Media: Viral transport media is the largest growing segment. These are essential kits that contain transport media in a tube as well as the swab.

• Blood Collection Kits: The blood collection kit is designed for use by medical personnel to aid in the collection of a whole blood sample.

• Others: Other product type includes specimen collection. This is the process of obtaining tissue or fluids for laboratory analysis or near-patient testing.

By Application

• Diagnostic: For diagnosis, the COVID-19 sample collection kit permits samples collected from the patient’s nose using a designated self-collection kit that contains nasal swabs and saline. This segment is the fastest-growing segment.

• Research: For research, the COVID-19 sample collection kit is used to collect samples from patients, and research is conducted for introducing vaccines or medications for preventing diseases. This segment is the largest growing segment.

By End-User

• Hospitals & Clinics: Hospitals & clinics segment is the largest segment with an increasing need for testing COVID-19 among communities. Many airtight cabins are arranged for collecting swab samples to prevent the infection from spreading. This is the largest growing segment.

• Diagnostics Centers: Diagnostic center is the fastest-growing segment. These centers help in the expansion of molecular diagnostic screening with increased usage of swabs and viral transport media for applications during diagnosis.

• Others: Other end-users include a home test, which enables an individual to collect a sample at home and prevent the transmission of diseases.

By Region

• Americas: According to the US Food and Drug Administration (FDA), April 2020, Laboratory Corporation of America (LabCorp) is the first diagnostic test developer for at-home specimen collection kit for COVID-19. This is expected for the high demand for sample collection kits across the region during the forecast period.

• Europe: As per MRFR, 2, 95,889 cases of COVID-19 were confirmed in the United Kingdom. Furthermore, according to the World Health Organization (WHO), January 2020 report, the World Health Organization (WHO), and the European Centre for Disease Prevention and Control (ECDC), moved quickly to identify the laboratory needs and capacities in the European region. Thus, sample collection kits are required for laboratory tests and detection due to a rise in the number of confirmed cases of COVID-19, which is expected to drive the market growth.

• Asia-Pacific: Due to the outbreak of COVID-19 cases, the Asian Development Bank (ADB), in March 2020, announced a USD 6.5 billion aid package for the Asia-Pacific region. Thus, an increase in government funding is expected to drive the market growth.

• Middle East & Africa: The Middle East & Africa region is more under proper infrastructure development and advancement of technology. This leads to low development in the healthcare industry which reduces the production of sample collection kits in the market. To overcome, rise in development and technology is expected to drive the market growth.

Key Players

• Thermo Fisher Scientific, Inc.


• Hardy Diagnostics


• BNTX Inc.


• Formlabs


• Medline Industries, Inc.


• HiMedia Laboratories


• VIRCELL S.L.


• Puritan Medical Products


• COPAN Diagnostics


• Becton, Dickinson, and Company


• Laboratory Corporation of America Holdings


• Lucence Diagnostics Pte Ltd.

Report Scope:

Report Attribute/Metric	Details
Market Size	2027: USD 4168.35 Million
CAGR	5.20% (2020-2027)
Base Year	2019
Forecast Period	2020-2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product Type and Application
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Thermo Fisher Scientific, Inc. (US), Hardy Diagnostics (US), BNTX Inc. (Germany), Formlabs (US), Medline Industries, Inc. (US), HiMedia Laboratories (India), VIRCELL S.L. (Spain), Puritan Medical Products (US), COPAN Diagnostics (California), Becton, Dickinson, and Company (US), Laboratory Corporation of America Holdings (US), Lucence Diagnostics Pte Ltd. (California).
Key Market Opportunities	The Outbreak of COVID-19, Leading to Increased Demand for the COVID-19 Sample Collection Kit.
Key Market Drivers	Approval of Detection Tests by Regulatory Authorities. Large Volume and Usage Rate of Swabs. Rise in the Detection of Antibodies. Increase in Government Funding. Rise in at-home kits for reducing the risk of transmitting the virus.\r\n